dc.contributor.author | Whittam, DH | |
dc.contributor.author | Karthikeayan, V | |
dc.contributor.author | Gibbons, E | |
dc.contributor.author | Kneen, R | |
dc.contributor.author | Chandratre, S | |
dc.contributor.author | Ciccarelli, O | |
dc.contributor.author | Hacohen, Y | |
dc.contributor.author | de Seze, J | |
dc.contributor.author | Deiva, K | |
dc.contributor.author | Hintzen, RQ | |
dc.contributor.author | Wildemann, B | |
dc.contributor.author | Jarius, S | |
dc.contributor.author | Broadley, S | |
dc.contributor.author | et al. | |
dc.date.accessioned | 2020-07-22T02:55:48Z | |
dc.date.available | 2020-07-22T02:55:48Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 0340-5354 | |
dc.identifier.doi | 10.1007/s00415-020-10026-y | |
dc.identifier.uri | http://hdl.handle.net/10072/395681 | |
dc.description.abstract | Introduction: While monophasic and relapsing forms of myelin oligodendrocyte glycoprotein antibody associated disorders (MOGAD) are increasingly diagnosed world-wide, consensus on management is yet to be developed. Objective: To survey the current global clinical practice of clinicians treating MOGAD. Method: Neurologists worldwide with expertise in treating MOGAD participated in an online survey (February–April 2019). Results: Fifty-two responses were received (response rate 60.5%) from 86 invited experts, comprising adult (78.8%, 41/52) and paediatric (21.2%, 11/52) neurologists in 22 countries. All treat acute attacks with high dose corticosteroids. If recovery is incomplete, 71.2% (37/52) proceed next to plasma exchange (PE). 45.5% (5/11) of paediatric neurologists use IV immunoglobulin (IVIg) in preference to PE. Following an acute attack, 55.8% (29/52) of respondents typically continue corticosteroids for ≥ 3 months; though less commonly when treating children. After an index event, 60% (31/51) usually start steroid-sparing maintenance therapy (MT); after ≥ 2 attacks 92.3% (48/52) would start MT. Repeat MOG antibody status is used by 52.9% (27/51) to help decide on MT initiation. Commonly used first line MTs in adults are azathioprine (30.8%, 16/52), mycophenolate mofetil (25.0%, 13/52) and rituximab (17.3%, 9/52). In children, IVIg is the preferred first line MT (54.5%; 6/11). Treatment response is monitored by MRI (53.8%; 28/52), optical coherence tomography (23.1%; 12/52) and MOG antibody titres (36.5%; 19/52). Regardless of monitoring results, 25.0% (13/52) would not stop MT. Conclusion: Current treatment of MOGAD is highly variable, indicating a need for consensus-based treatment guidelines, while awaiting definitive clinical trials. | |
dc.description.peerreviewed | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | Springer | |
dc.relation.ispartofjournal | Journal of Neurology | |
dc.subject.fieldofresearch | Clinical sciences | |
dc.subject.fieldofresearch | Neurosciences | |
dc.subject.fieldofresearchcode | 3202 | |
dc.subject.fieldofresearchcode | 3209 | |
dc.subject.keywords | Science & Technology | |
dc.subject.keywords | Life Sciences & Biomedicine | |
dc.subject.keywords | Clinical Neurology | |
dc.subject.keywords | Myelin oligodendrocyte glycoprotein | |
dc.subject.keywords | Neurology | |
dc.title | Treatment of MOG antibody associated disorders: results of an international survey | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dcterms.bibliographicCitation | Whittam, DH; Karthikeayan, V; Gibbons, E; Kneen, R; Chandratre, S; Ciccarelli, O; Hacohen, Y; de Seze, J; Deiva, K; Hintzen, RQ; Wildemann, B; Jarius, S; Broadley, S; et al., A, Treatment of MOG antibody associated disorders: results of an international survey, Journal of Neurology, 2020 | |
dcterms.dateAccepted | 2020-06-25 | |
dc.date.updated | 2020-07-22T01:55:05Z | |
gro.description.notepublic | This publication has been entered in Griffith Research Online as an Advance Online Version. | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Broadley, Simon | |